Welcome to our dedicated page for Elite Pharmaceuticals SEC filings (Ticker: ELTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elite Pharmaceuticals, Inc. filings document a Nevada specialty pharmaceutical issuer with common stock trading under ELTP on the OTCQB. The company's SEC reports include Form 8-K disclosures for quarterly results, Regulation FD updates, press-release exhibits, and amendments to current reports.
Recent filings describe financial-result announcements linked to Form 10-Q reporting, FDA approval and launch disclosures for generic drug products, and product marketing under the Elite Laboratories, Inc. label. The filing record also identifies the company's common stock class and provides formal notice of material events related to its niche generic pharmaceutical business.
Elite Pharmaceuticals (ELTP) announced it will host a conference call to discuss its second quarter fiscal 2026 results for the period ended September 30, 2025. The call is scheduled for November 14, 2025, at 11:30 AM EST.
Participants can dial 1-800-346-7359 (domestic) or 1-973-528-0008 (international) and use conference number 98840. Questions may be emailed to dianne@elitepharma.com; general questions are due by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025.
Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.
The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.